FINNENCE ▪ THE WIRE FILE
THE WIRE · № 55424
News■ Unclear/unknown
Impruvon to Streamline Missouri's Statewide Medication Management & HRST Automation
KINDNews
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN2026-09-29 15:30 UTC
LAST UPDATE2026-09-29 15:30 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
A state medication-management contract lacks disclosed value or public-company exposure.
Public-sector health IT deal, private counterparty
CATALYST TO WATCH
Contract value disclosure or expansion
MAIN RISK
Private company, no tradable exposure
FULL DISPATCH
ST. LOUIS, Sept. 29, 2026 /PRNewswire/ -- Impruvon, a leader in medication management and clinical workflow solutions for individuals with intellectual and developmental disabilities (I/DD), today announced a partnership with the Missouri Department of Mental Health, Division of...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
Smart Ring Maker Oura Delays IPO Due to Market ‘Uncertainty’2026-09-29 11:48 UTC
Smart Ring Maker Oura Delays IPO Due to Market ‘Uncertainty’2026-09-29 11:48 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: Study to Assess the Long-term Safety of KN3835 in the Treatment and Retreatment of Flexible/Semi-Flexible Hammertoe (HMT) — Endo USA Inc., a Keenova Therapeutics Company2026-09-29 12:00 UTC
New Phase 3 trial: Study to Assess the Long-term Safety of KN3835 in the Treatment and Retreatment of Flexible/Semi-Flexible Hammertoe (HMT) — Endo USA Inc., a Keenova Therapeutics Company2026-09-29 12:00 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: Study of Velaglucerase Beta ERT in Children With Gaucher Disease — CANbridge Life Sciences Ltd.2026-09-29 12:00 UTC
New Phase 3 trial: Study of Velaglucerase Beta ERT in Children With Gaucher Disease — CANbridge Life Sciences Ltd.2026-09-29 12:00 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity — Pfizer2026-09-29 12:00 UTC
New Phase 3 trial: A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity — Pfizer2026-09-29 12:00 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: A Study to Assess the Efficacy and Safety of Afimkibart for Induction Therapy in Participants With Moderately to Severely Active Ulcerative Colitis — Hoffmann-La Roche2026-09-29 12:00 UTC
New Phase 3 trial: A Study to Assess the Efficacy and Safety of Afimkibart for Induction Therapy in Participants With Moderately to Severely Active Ulcerative Colitis — Hoffmann-La Roche2026-09-29 12:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.